BioNTech (NASDAQ:BNTX) Earns “Buy” Rating from Berenberg Bank

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by Berenberg Bank in a note issued to investors on Monday,MarketScreener reports.

A number of other brokerages also recently commented on BNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Wednesday. BMO Capital Markets reduced their target price on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday, March 25th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.13.

BioNTech Stock Performance

NASDAQ:BNTX opened at $98.09 on Monday. The company has a fifty day simple moving average of $98.81 and a two-hundred day simple moving average of $101.05. The company has a market cap of $24.80 billion, a price-to-earnings ratio of -18.67 and a beta of 1.58. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. As a group, equities analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. Kennedy Capital Management LLC raised its stake in shares of BioNTech by 0.6% in the 4th quarter. Kennedy Capital Management LLC now owns 21,065 shares of the company’s stock valued at $2,005,000 after acquiring an additional 134 shares during the period. Probity Advisors Inc. raised its stake in shares of BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after acquiring an additional 135 shares during the period. Mackenzie Financial Corp raised its stake in shares of BioNTech by 4.0% in the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock valued at $418,000 after acquiring an additional 165 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of BioNTech by 40.8% in the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock valued at $77,000 after acquiring an additional 227 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.